Center for Drug Evaluation and Research Director Janet Woodcock's performance at the Feb. 4 House hearing on drug pricing offered another example of why she is such a key asset to FDA, but also illustrated that congressional overseers may not have a great deal of appreciation for the agency itself.
FDA came under fire for its backlog of generic applications during the House Oversight & Government Reform Committee hearing, which focused primarily on the pricing activities of Turing Pharmaceuticals AG